Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acura Pharmaceuticals and King Pharmaceuticals have announced that King has exercised its option to license a fourth immediate-release opioid analgesic product candidate utilizing Acura's proprietary Aversion technology.
Subscribe to our email newsletter
In connection with the exercise of its option, King has paid Acura an option exercise fee of $3 million. Products utilizing Aversion technology are designed to deter common methods of prescription drug misuse and abuse.
Along with this fourth opioid product candidate, King and Acura are jointly developing three other opioid analgesic product candidates utilizing Acura’s Aversion technology, including Acurox (oxycodone HCl/niacin) tablets. All of these product candidates have been licensed by Acura to King pursuant to an October 2007 license, development and commercialization agreement.
The agreement provides King with an option to license all opioid analgesic products utilizing Aversion technology for development and commercialization in the US, Canada and Mexico.